Literature DB >> 25706706

Sorafenib for patients with differentiated thyroid cancer--authors' reply.

Marcia S Brose1, Martin Schlumberger2, Carol Peña3, Christian Kappeler4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25706706     DOI： 10.1016/S0140-6736(15)60056-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.

Authors:  Francis Worden; Martin Fassnacht; Yuankai Shi; Tatiana Hadjieva; Françoise Bonichon; Ming Gao; Laura Fugazzola; Yuichi Ando; Yasuhisa Hasegawa; Do Joon Park; Young Kee Shong; Johannes W A Smit; John Chung; Christian Kappeler; Gerold Meinhardt; Martin Schlumberger; Marcia S Brose
Journal:  Endocr Relat Cancer       Date:  2015-12       Impact factor: 5.678

Review 2.  Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer-Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension.

Authors:  Anne Christine Kaae; Michael C Kreissl; Marcus Krüger; Manfred Infanger; Daniela Grimm; Markus Wehland
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.